<DOC>
	<DOCNO>NCT00939952</DOCNO>
	<brief_summary>The objective study characterize pharmacokinetic profile ertapenem continuous ambulatory peritoneal dialysis ( CAPD ) .</brief_summary>
	<brief_title>Ertapenem Pharmacokinetics Patients Continuous Ambulatory Peritoneal Dialysis</brief_title>
	<detailed_description>BACKGROUND : Infection lead cause morbidity mortality end-stage renal disease ( ESRD ) patient . [ 1 , 2 ] Ertapenem antibiotic use treatment infection cause several organism , include Gram positive negative infections.3 Although ertapenem pharmacokinetic ( PK ) parameter describe general population , information patient peritoneal dialysis available . Determining optimal antibiotic dosing recommendation ertapenem imperative health CAPD patient order prevent either excess medication sub-therapeutic dos drug . This study provide clinician necessary information safely effectively treat CAPD patient ertapenem . OBJECTIVE The objective study characterize pharmacokinetic profile ertapenem continuous ambulatory peritoneal dialysis ( CAPD ) . RESEARCH DESIGN &amp; METHODS : Study Location This study conduct outpatient dialysis clinic ( Hortense Louis Rubin Dialysis Center , Clifton Park , NY ) , blood , dialysate , urine sample occur . Study Population To accomplish study objective , prospective , open-label , pharmacokinetic study ertapenem 8 patient CAPD conduct . The desired composition study population consist approximately 4 male 4 female , 6 Caucasian , 2 non-Caucasian patient . This patient composition select reflect demographic Hortense Louis Rubin Dialysis Center , Clifton Park , NY . . Inclusion criterion Adult patient ( ≥ 18 year ) , non-infected ( afebrile , lack constitutional symptom leukocytosis ) , stable PD regimen ( least one month ) eligible participation . Both patient without residual renal function study . Non-anuric patient concurrently receive medication potential inhibit active tubular secretion allow enter study 2-week washout period . These medication include H2-antagonists , trimethoprim , probenecid . The patient physician Hortense Louis Rubin Dialysis Center contact medication need discontinue . ii . Exclusion criteria Patients ineligible study peritonitis within previous 4 week , clinical sign symptom active infection , elevate white blood cell count , treatment antibiotic within previous 2 week . Patients hemoglobin ( hgb ) &lt; 11 g/dL ineligible study inclusion . Patients state documented allergy beta-lactams medication eligible . Pregnant breastfeed woman eligible inclusion . All woman child-bearing age need yield serum hCG ≤ 5 mIU/mL within 2 week schedule study day . Patients take valproic acid also exclude . Research Plan Prior initiation study protocol , informed consent obtain participant . A translator consult accommodate non-English speaking study patient . i. Dialysis Prescription Eligible patient receive standardize CAPD prescription 4 daily exchange 2 L 2.5 % dextrose dialysate , dwell period 6 hour , 4 hour , 6 hour 8 hour , respectively , start 7 day prior ertapenem administration day . On study day , patient perform 2 exchange Hortense Louis Rubin Dialysis Center . ii . Pre-Ertapenem Administration Procedure Two week prior study day , woman child-bearing age require yield negative pregnancy test ( hCG ≤ 5 mIU/mL ) . One week prior study day , complete blood count ( CBC ) check ensure Hb concentration ≥11 g/dL white blood cell ( WBC ) count normal ( 5-10,000 cells/mm3 ) . The patient ' weight also record time . On study day , patient arrive dialysis clinic , drain peritoneal cavity instill fresh dialysate way PD catheter 5 - 10 minute use Y-type administration set . Spent dialysate precede exchange drain immediately prior intravenous injection ertapenem . Patients residual renal function urinate immediately prior administration ertapenem . An aliquot ( 10 mL ) urine save tested ensure interfere substance present would invalidate assay use ertapenem determination urine . Patients two peripheral venous catheter place : 1 ) drug administration 2 ) blood sampling purpose . iii . Ertapenem Administration On study day , subject give ertapenem 500 mg IV 30 minute infusion . iv . Blood Dialysate Sampling Patients perform 2 CAPD exchange study period , 13 blood sample 13 dialysate sample collect ( see figure ) . v. Urine Collection Non-anuric patient require collect urine course study period . vi . Sample preparation assay method The urine , plasma , dialysate concentration ertapenem determine high pressure liquid chromatography ( HPLC ) liquid chromatography / mass spectrometry ( LCMS ) device . Blood sample collect standard blood collection tube contain sodium heparin maximum volume 4 mL . Samples store ice plasma harvest ( within 2 hour ) . Plasma obtain place blood sample centrifuge room temperature approximately 3000 - 4000 rpm 15 minute . The plasma withdrawn , split 2 aliquot equal volume , transfer separate polypropylene tube ( Tube 1 , Tube 2 ) . The tubes pre-labeled either Set A ( Tube 1 ) Set B ( Tube 2 ) . The label indelible ink . The following information include label : sample type ( plasma ) , dose number sample collect ( i.e. , dose # 3 ) , protocol number , subject number , date time sample . Similarly dialysate urine sample split two batch store -20oC assayed . The dialysate mixed thoroughly . The total sample volume record . Two milliliter dialysate transfer polypropylene tube ( Tube 1 Tube 2 ) . The tubes pre-labeled either Set A ( Tube 1 ) Set B ( Tube 2 ) . The label indelible ink . The following information include label : sample type ( dialysate ) , dose number sample collect ( i.e. , dose # 3 ) , protocol number , subject number , date time sample . Samples store frozen -20 degree Centigrade ship concentration determination . Blank dialysate ( without ertapenem ) also send assay assess potential interfering substance assay serve analytical control assay . The blank dialysate sample 10-20 mL store individual polypropylene tube , clearly mark , `` dialysis blank . '' On separate piece paper , specific concentration component dialysate fluid ( i.e. , electrolytes , dextrose , saline , etc . ) include shipment . Urine collect split two aliquot equal volume transfer polypropylene tube ( Tube 1 Tube 2 ) . The tubes pre-labeled Tube A ( Tube 1 ) Tube B ( Tube 2 ) . Tubes pre-labeled indelible ink include follow information : sample type ( urine ) , protocol number , subject number . Samples store frozen -20 degree Centigrade ship ertapenem concentration determination . One batch dialysate sample pack dry ice ( sufficient 2 day ) ship location determine Merck . One batch blood urine sample pack dry ice ( sufficient 2 day ) ship location determine Merck . The second batch sample ( dialysate , blood , urine ) send central laboratory ( Quest Diagnostics , Inc ) serum , urine , dialysate creatinine urea assay dialysate dextrose concentration assay . Data Analysis : All pharmacokinetic data analyze population pharmacokinetic model use Non Parametric Adaptive Grid adaptive γ ( NPAG ) program Leary , Schumitzky Jelliffe.5 Upon obtain model convergence , mean parameter vector covariance matrix population pharmacokinetic analysis embed Subroutine Prior ADAPT II package program D'Argenio Schumitzky.6 The following differential equation use characterize PK profile ertapenem : 〖dX〗_1/dt=R_1- ( k_12+CL/V+k_13 R_2+k_13 R_3 ) X_1+k_21 X_2+k_31 X_3 R_2+k_31 X_4 R_3 〖dX〗_2/dt=k_12 X_1-k_21 X_2 〖dX〗_3/dt=k_13 X_1 R_2-k_31 X_3 R_2 〖dX〗_4/dt=k_13 X_1 R_3-k_31 X_4 R_3+R_4 R_5 〖CONEX〗_1 X1 : amount drug central compartment ; X2 : amount drug peripheral compartment ; X3 : amount drug first peritoneal exchange ; X4 : amount drug second peritoneal exchange ; CL : non-dialytic clearance central compartment ( liter per hour ) ; V : volume central compartment ( liter ) ; k12 k21 : first-order intercompartmental transfer rate constant central peripheral compartment ( inverse hour ) ; k13 k31 : first-order intercompartmental transfer rate constant central peritoneal compartment ; CONEX1 : amount ertapenem remain peritoneal compartment drainage first study exchange ( mg ) ; R1 : time-delimited zero-order drug input rate ( piece-wise input function ) central compartment ( mg per hour ) ; R2 : rate constant first dwell constrain 0 ( first dwell turn ) 1 ( first dwell turn ) ; R3 : rate constant second dwell constrain 0 ( second dwell turn ) 1 ( second dwell turn ) ; R4 : ertapenem dialysate concentration observe end first dwell ; R5 : input rate residual amount dialysate volume remain drainage first dwell . The population simulation without process noise option employ . A 9,999 subject Monte Carlo simulation perform examine array potential ertapenem candidate dose regimen CAPD . REFERENCES 1 . Bloembergen WE , Port FK . Epidemiological perspective infection chronic dialysis patient . Adv Ren Replace Ther . Jul 1996 ; 3 ( 3 ) :201-207 . 2 . United States Renal Data System . USRDS Annual Data Report : Atlas End-stage Renal Disease United States . Bethesda , MD : National Institute Health , National Institute Diabetes Digestive Kidney Diseases ; 2007 . 3 . Merck &amp; Co , Inc. Invanz ( ertapenem ) package insert . Whitehouse Station , NJ ; 2008 . 4 . D'Argenio DZ , Schumitzky A . A program package simulation parameter estimation pharmacokinetic system . Comput Programs Biomed . Mar 1979 ; 9 ( 2 ) :115-134 . 5 . Leary , R. , R. Jelliffe , A. Schumitzky , M. van Guilder . An adaptive grid , non-parametric approach pharmacokinetic dynamic ( PK/PD ) model . Proceedings , Fourteenth IEEE Symposium Computer-Based Medical Systems . 26-27 July 2001 . Bethesda , MD , IEEE Computer Society , pp . 389-394 . 6 . D'Argenio , D. Z. , A. Schumitzky . 1979 . A program package simulation parameter estimation pharmacokinetic system . Comput Programs Biomed 9:115-34 .</detailed_description>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Ertapenem</mesh_term>
	<criteria>. Inclusion criterion Adult patient ( ≥ 18 year ) , noninfected ( afebrile , lack constitutional symptom leukocytosis ) , stable PD regimen ( least one month ) eligible participation . Both patient without residual renal function study . Nonanuric patient concurrently receive medication potential inhibit active tubular secretion allow enter study 2week washout period . These medication include H2antagonists , trimethoprim , probenecid . The patient physician Hortense Louis Rubin Dialysis Center contact medication need discontinue . ii . Exclusion criteria Patients ineligible study peritonitis within previous 4 week , clinical sign symptom active infection , elevate white blood cell count , treatment antibiotic within previous 2 week . Patients hemoglobin ( hgb ) &lt; 11 g/dL ineligible study inclusion . Patients state documented allergy betalactams medication eligible . Pregnant breastfeed woman eligible inclusion . All woman childbearing age need yield serum hCG ≤ 5 mIU/mL within 2 week schedule study day . Patients take valproic acid also exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>ertapenem</keyword>
	<keyword>CAPD</keyword>
	<keyword>dialysis</keyword>
</DOC>